To learn more about how we handle and protect your data, visit our privacy center. Maintaining independence and editorial freedom is essential to our mission of empowering investor success.

Eli Lilly and Co. plans to set up a $31 million digital health innovation hub in Singapore, expanding its research and ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily outperforming both the S&P 500 and Nasdaq Composite indexes. Much of the ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE ... to create an advanced manufacturing and drug development center at its Indiana facility, which comes on the heels ...

Shares of Eli Lilly and Co. slumped toward their biggest ... Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter ...

Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by ...

England’s drug-cost regulator rejected Eli Lilly’s Alzheimer’s drug for use in the country’s public health system, marking the second time a treatment for the disease has been deemed too ...